Takeda and Eli Lilly Sued Over Actos Bladder Cancer Claims
The law firm of Baum, Hedlund, Aristei & Goldman has filed lawsuits on behalf of several people who claim their bladder cancer was caused by taking a diabetes drug called Actos (pioglitazine). The lawsuits were filed in federal court in Louisiana and California state court against Takeda Pharmaceutical Company USA and Eli Lilly, the companies that manufactured Actos and brought the drug to market in the US.
Five of the lawsuits joined at least 4,000 other Actos cases consolidated in the multi-district litigation (MDL No. 6:11-md-2299) before the Honorable Judge Rebecca Doherty of the U.S. District Court for the Western District of Louisiana. Dick Hopkins of Gig Harbor, Washington and Donald McQuinn, Sr. of Westfield, North Carolina are two of the five plaintiffs who claim to have developed bladder cancer as a result of taking Actos.
All of the plaintiffs involved in these cases allege that Takeda promoted Actos as a safe and effective way to treat diabetes, even though the company knew about dangerous side effects associated with the drug. According to the lawsuits, Takeda became aware of these side effects dating back to the 1990's and rather than warning the patients and the medical community about the drug's dangers, they continued to market Actos as safe and effective.Plaintiffs in the lawsuits say if they had known about the dangers associated with the drug, they would have never taken it. They are seeking punitive damages for Takeda and Eli Lilly's negligence in an effort to stop Takeda and other drug companies from similar conduct.
Judge Denies Motion to Overturn $9 Billion Actos Jury Award
A federal judge has denied a motion by Takeda Pharmaceuticals and Eli Lilly and Company to overturn the verdict of a jury that recently ordered the two drug makers to pay $1.5 million in compensatory damages and $9 billion in punitive damages to the plaintiff after finding that Takeda hid evidence linking its diabetes drug, Actos, to an increased risk of bladder cancer. The plaintiff in the case, Terrance Allen, blamed Actos for his bladder cancer.
Insurance Company Files Actos Bladder Cancer Lawsuit
Blue Cross and Blue Shield of Massachusetts (BCBSMA) has filed a lawsuit, on behalf of its insured members, against Takeda Pharmaceuticals, maker of the diabetes drug, Actos. The suit charges the Japanese company with hiding evidence that Actos causes bladder cancer and also names Takeda’s U.S. marketing partner, Eli Lilly and Company.
A federal judge in Louisiana has ruled that Takeda Pharmaceuticals intentionally destroyed evidence relevant to multidistrict litigation involving Takeda’s diabetes drug Actos. The ruling affects over 6,000 lawsuits that have been consolidated before U.S. District Judge Rebecca Doherty, who issued today’s ruling. Plaintiffs in those cases have charged Takeda with concealing evidence and failing to warn patients and health care providers that Actos significantly increases the risk of bladder cancer.
A District Court judge has issued sanctions against lawyers for Takeda Pharmaceuticals in a trial currently underway in Las Vegas. In an order filed yesterday, the judge ruled that attorneys for Takeda violated pretrial evidentiary rulings nine times and “repeatedly engaged in disruptive and disrespectful behavior towards the court.” Plaintiffs in the case, Delores Cipriano, 81, of Henderson, NV, and Bertha Triana, 80, of Las Vegas, are both suffering from bladder cancer, which they claim was caused by Takeda’s diabetes drug, Actos. They are seeking a multibillion-dollar verdict against the Japanese drug maker.
Takeda, Lilly Jury Awards $9 Billion Over Actos Risks
Trial Starts for Two Nevada Women who Developed Bladder Cancer after taking Actos